NCT04306146View on ClinicalTrials.gov

Study of CAD-9303 in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

September 22, 2021

Study Completion Date

November 24, 2021

Conditions
Schizophrenia
Interventions
DRUG

CAD-9303

Capsules filled with CAD-9303 from 3 mg up to 1000 mg.

DRUG

Placebos

Capsules

Trial Locations (2)

90806

Collaborative Neuroscience Research, Long Beach

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Cadent Therapeutics

INDUSTRY